Interwell Health Names Carney Taylor as CMO to Steer Clinical Strategy Amid Value-Based Growth

New updates have been reported about Interwell Health.

Interwell Health has appointed longtime nephrology leader Carney Taylor, MD, MBA, as chief medical officer, a key leadership move as the company accelerates its value-based kidney care strategy under Fresenius Medical Care. Taylor succeeds former CMO Dr. George Hart, who retired from the role on January 1 but will remain as a strategic advisor to ensure continuity in clinical strategy, quality programs, and physician network engagement during the transition. CEO Tommy O’Connor emphasized that Taylor’s decades of hands-on patient care and his collaborative leadership style are central to aligning the company’s 2,300-network nephrologists around Interwell’s long-term clinical direction and performance objectives.

Taylor brings more than 25 years of nephrology and practice administration experience, including prior service as Interwell’s associate CMO and as a board member, and earlier as co-president of Eastern Nephrology Associates, one of the earliest and most engaged partners in federal value-based kidney care models. In his new role, he will be responsible for sustaining and scaling Interwell’s outcomes-focused model as payers increasingly demand physician-led, cost-efficient solutions for high-risk kidney populations nationwide. Interwell positions its integrated approach—combining a nephrology-specific EHR, advanced data and machine learning capabilities, and coordinated interdisciplinary care teams across all 50 states and Puerto Rico—as a lever to deliver measurable savings for payers and improved clinical outcomes, while reinforcing physician satisfaction and retention. The leadership transition, following the recent appointment of O’Connor as CEO, signals a continued push to expand Interwell’s footprint and deepen its role as Fresenius Medical Care’s value-based care engine in chronic kidney disease and kidney failure management.